Previous 10 | Next 10 |
With a significant portion of the world still in lockdown due to the COVID-19 pandemic, many investors are anxious about how soon a vaccine can be developed to combat the coronavirus. Currently, one of the most promising candidates for this challenge is Moderna 's (NASDAQ: MRNA) mRNA-1273 vac...
Stocks dipped on Friday as tensions between China and the U.S. offset the increasing optimism around a potential coronavirus vaccine. The Dow Jones Industrials lost another 139.54 points to move into the final session before a long weekend at 24,334.58. The S&P 500 docked 10.19 p...
U.S. stock futures rose slightly early Friday as Wall Street wrapped up a winning week. Futures for Dow Jones Industrials advanced 45 points, or 0.2%, early Friday to 24,421. Futures for the S&P 500 sailed 6.5 points, or 0.4%, higher at 2,943.50. Futures for the NASDAQ Composit...
"Having looked at the data," it is "quite promising", NIH's Dr. Anthony Fauci said in an interview on NPR of Moderna's (NASDAQ: MRNA ) new efforts and it's Phase 1 trial. More news on: Moderna, Inc., SPDR S&P 500 Trust ETF, News on the U.S. economy, News on ETFs, Read m...
It's been a monumental few days for Moderna (NASDAQ: MRNA) . Its stock experienced a significant spike on Monday after the pharma giant announced that phase 1 trials for its prospective COVID-19 vaccine, mRNA-1273, showed promising interim results. Shares closed almost 20% higher on Mond...
Moderna (NASDAQ: MRNA) shares soared 20% in one trading session on Monday after the company reported positive interim data from its coronavirus vaccine clinical trial. The data is indeed promising -- across all participants in two dosage groups, levels of binding antibodies were at...
Shares of Moderna (NASDAQ: MRNA) fell nearly 9% on Thursday, continuing a downward trend that began soon after the biotechnology company's recent stock sale. Moderna's stock soared on Monday after it released positive data from its phase 1 study for mRNA-1273, its coronavirus vaccine...
Moderna CEO Bancel served investors lemonade before the market opened on Monday at the interim phase 1 SARS-CoV-2 vaccine data conference. As of Tuesday’s market close the stock has nearly filled in Monday’s gap up. Bancel’s vague responses to very appropriate questions fr...
I started writing this article a few days ago, but Tuesday's close is a great example of how strange this market is. Tuesday, the market is up the entire day 70bps or so. Not unusual of late. Then, it turns out Moderna ( MRNA ), a company that's working on a vaccine, may have misrepresented i...
In a note, Evercore ISI's Joshua Schimmer says Moderna's (NASDAQ: MRNA ) COVID-19 vaccine, mRNA-1273, is unlikely to be the best of the bunch but may wind up being "good enough" to get the first regulatory nod, adding that other candidates appear poised to offer higher immunogenicity, fewer ...
News, Short Squeeze, Breakout and More Instantly...
On CNBC's “Mad Money Lightning Round,” Jim Cramer believes in Moderna, Inc. (NASDAQ:MRNA). On May 14, Evercore ISI Group analyst C...
2024-05-14 06:35:00 ET Investors have put their hopes in Moderna 's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it represents a new revenue stream for a company that until now has relied on just one product, and a product strugg...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 27.7% on an annualized basis producing an average annual return of 40.43...